<DOC>
	<DOCNO>NCT02332889</DOCNO>
	<brief_summary>The main purpose study determine safety use combination decitabine cancer vaccine plus Hiltonol . The vaccine make subject 's blood cell design interact subject 's body cell program fight specific tumor protein call NY-ESO-1 , MAGE-A1 MAGE-A3 . The decitabine give increase amount activity cancer proteins surface tumor cell increase possibility vaccine stimulate cell act tumor cell . Subjects assess determine tumor respond treatment .</brief_summary>
	<brief_title>Phase I/II : Decitabine/Vaccine Therapy Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs</brief_title>
	<detailed_description>One challenge practical application immunotherapy brain tumor lack expression tumor antigen well down-regulation MHC Class I II molecule , need antigen presentation . Considering ability DAC facilitate expression CT antigens MHC molecule fact good blood brain barrier penetration , reasonable test approach vaccine study patient experience disease recurrence . The use combine approach tumor immunotherapy - antigen upregulation follow vaccination - study patient population , strong biologic rationale strategy . Patients pediatric brain tumor ( medulloblastoma , CNS PNET , high grade glioma ) experience disease relapse progressive refractory disease eligible . Each cycle consist DAC low dose administer 5 day period , follow two weekly vaccination consist autologous dendritic cell pulse pool , overlap peptide mix derive full-length MAGE-A1 , MAGE-A3 , NY-ESO-1 . This dose DAC low previously report dos safely administer adult patient MDS AML , use previous protocol relapse refractory pediatric neuroblastoma sarcoma . A novel way stimulate CD4 CD8 antigen specific T cell use DC vaccine approach cell pulse overlap peptide derive antigen , patient several different HLA background enrol . Overlapping peptide mix derive full-length NY-ESO-1 , MAGE-A1 , MAGE-A3 acquire JPT Peptide Technologies , consist 15-mers , 11 amino acid overlap . The number DC give study ( 8-10 x 106 peptide pulse DC ) within range dos give previous study . Vaccinations space weekly interval , base multiple previous study approach take , fact vitro re-stimulation CTL generally occur weekly basis . GM-CSF give day 1 5 vaccine week , minimize leukopenia DAC help facilitate antigen present cell function . The adjuvant poly-ICLC ( Hiltonol ) inject immediately adjacent DC vaccine site enhance DC maturation . We accrue 10 patient relapse , refractory , progressive pediatric brain tumor 3 year period . Cycles repeat every five week , two cycle . Patients disease progression two cycle may receive additional two cycle therapy .</detailed_description>
	<mesh_term>Glioma</mesh_term>
	<mesh_term>Neuroectodermal Tumors</mesh_term>
	<mesh_term>Neuroectodermal Tumors , Primitive</mesh_term>
	<mesh_term>Medulloblastoma</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Poly ICLC</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<criteria>Criteria enrollment : Relapsed medulloblastoma , CNS PNET , high grade glioma . Confirmatory biopsy require time initial diagnosis . Because rapid clinical progression decline time relapse patient grade IV glioma DIPGs , 46 week require develop vaccine , patient tumor eligible enroll DCs harvest stored time diagnosis , treat vaccine time relapse . Age : Patients must 2 25 year age . Criteria treatment : The patient must experience relapse , progressive , refractory disease . The patient may gross tumor treat chemotherapy radiation prior study treatment . The patient must receive standard therapy tumor . The patient must least 90 day primary radiotherapy . Hematologic Function : ANC : 1000/uL ; Platelet count : 75,000/uL . Renal Function : Creatinine clearance radioisotope GFR 70ml/min/1.73 m2 . Cardiac Function : Patient must normal cardiac function document : Ejection fraction ( &gt; 55 % ) document echocardiogram radionuclide MUGA evaluation OR Fractional shortening ( â‰¥28 % ) document echocardiogram Liver Function : Total bilirubin 1.5x normal age , SGPT ( ALT ) SGOT ( AST ) 3x normal age . Room air pulse oximetry &gt; 94 % . Male female sexually active patient reproductive age wish participate must agree use acceptable contraception . Lansky/Karnofsky performance scale &gt; 50 , ECOG &lt; = 2 ( Appendix I ) . Patient pregnant . Patients positive result follow diagnostic test : Hep B Ag , Hep B Core Ab , Hep C Ab , HIV1 Ab , HIV2 Ab , HTLV1 Ab , HTLV2 Ab , RPR . Patient history autoimmune disease , specifically inflammatory bowel disease , systemic lupus erythematosis , rheumatoid arthritis . Patient receive high dos systemic corticosteroid concurrent chemotherapy time begin study treatment . ( Maximum dose dexamethasone allow 0.1mg/kg/day exceed 4mg/day . ) Patient know systemic hypersensitivity DAC , Hiltonol , vaccine component .</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>